Clinical Trial Update: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

A pediatric and young adult phase 1/2 trial is studying lurbinectedin as monotherapy for relapsed/refractory Ewing sarcoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma

Drugs mentioned

• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma | Phase 1, Phase 2 | Status: RECRUITING